Lineage Cell Therapeutics (NYSEMKT:LCTX) just reported results for the first quarter of 2024.
- Lineage Cell Therapeutics reported earnings per share of -4 cents. This met the analyst estimate for EPS of -4 cents.
- The company reported revenue of $1.44 million.
- This was 6.18% better than the analyst estimate for revenue of $1.36 million.